Loading...
XSHE300142
Market cap2.44bUSD
Jan 16, Last price  
11.47CNY
1D
-0.52%
1Q
-22.60%
Jan 2017
5.23%
IPO
-29.28%
Name

Walvax Biotechnology Co Ltd

Chart & Performance

D1W1MN
XSHE:300142 chart
P/E
42.64
P/S
4.35
EPS
0.27
Div Yield, %
0.09%
Shrs. gr., 5y
0.80%
Rev. gr., 5y
36.16%
Revenues
4.11b
-19.12%
129,361,532184,061,893239,129,713358,792,291473,810,891537,558,541583,094,757719,021,3111,006,027,016591,004,603668,264,842879,044,6961,121,220,2882,939,021,2193,462,831,0945,086,445,1954,113,772,326
Net income
419m
-42.44%
7,424,57934,700,00276,331,360154,416,606207,537,629232,803,21747,893,080143,424,674070,458,70101,046,204,465194,135,6481,003,186,827601,351,852728,652,009419,390,211
CFO
1.13b
-5.64%
31,845,105082,184,37686,711,20291,977,91578,380,60200000062,016,820114,192,983705,276,7501,201,491,0081,133,768,797
Dividend
May 30, 20240.01 CNY/sh
Earnings
Apr 18, 2025

Profile

Walvax Biotechnology Co., Ltd., a biological pharmaceutical company, researches and develops, produces, and sells bio-medicine products in China. The company offers biomedicines, such as vaccines, blood products, and others. It provides Group A, C meningococcal polysaccharide conjugate vaccine for infants below or equal to 2 years preventing diseases, such as cerebrospinal meningitis and septicemia; Group A and C meningococcal polysaccharide vaccine for in adults and children over the age of 2 years and adults to prevent disease caused by the bacterium Neisseria meningitidis group A or group C; and Group ACYW135 meningococcal polysaccharide vaccine for children above 2 years old to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis group A, C, Y, and W135. The company also offers haemophilus influenzae type b conjugate vaccine for children from the age of 2 months to 5 years for the prevention of infectious diseases, including meningitis, pneumonia, septicemia, cellulitis, arthritis, epiglottitis, etc. In addition, it provides diphtheria, tetanus, and acellular pertussis combined vaccine for the prevention of diphtheria, tetanus, and pertussis for individuals from the age of 3 months to 6 years; and 23-valent pneumococcal polysaccharide vaccine for children above 2 years old to prevent pneumococcal disease caused by 23 serotypes. Walvax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Kunming, China.
URL
https://www.walvax.com/
IPO date
Nov 12, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,113,772
-19.12%
5,086,445
46.89%
Cost of revenue
3,101,206
3,668,105
Unusual Expense (Income)
NOPBT
1,012,566
1,418,340
NOPBT Margin
24.61%
27.88%
Operating Taxes
87,651
132,239
Tax Rate
8.66%
9.32%
NOPAT
924,915
1,286,101
Net income
419,390
-42.44%
728,652
21.17%
Dividends
(15,993)
(43,242)
Dividend yield
0.04%
0.07%
Proceeds from repurchase of equity
(72,213)
(1)
BB yield
0.19%
0.00%
Debt
Debt current
320,271
120,531
Long-term debt
476,086
369,717
Deferred revenue
423,327
404,526
Other long-term liabilities
42,076
1
Net debt
(4,625,520)
(4,713,093)
Cash flow
Cash from operating activities
1,133,769
1,201,491
CAPEX
(945,516)
Cash from investing activities
(810,278)
Cash from financing activities
236,644
94,818
FCF
261,361
358,544
Balance
Cash
4,364,535
3,873,475
Long term investments
1,057,341
1,329,866
Excess cash
5,216,187
4,949,019
Stockholders' equity
6,556,269
6,790,106
Invested Capital
7,420,336
6,862,537
ROIC
12.95%
20.28%
ROCE
7.97%
11.92%
EV
Common stock shares outstanding
1,600,115
1,603,548
Price
23.51
-41.50%
40.19
-28.49%
Market cap
37,618,711
-41.63%
64,446,575
-28.39%
EV
35,039,275
61,639,201
EBITDA
1,329,798
1,683,271
EV/EBITDA
26.35
36.62
Interest
3,808
7,107
Interest/NOPBT
0.38%
0.50%